Celldex announced multiple presentations on barzolvolimab's effectiveness in treating chronic urticarias at the upcoming AAAAI Annual Meeting.
Quiver AI Summary
Celldex (NASDAQ:CLDX) announced that it will present findings from its Phase 2 clinical trials on barzolvolimab, aimed at treating chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), at the 2026 AAAAI Annual Meeting in Philadelphia from February 27 to March 2. A late-breaking abstract will showcase new data indicating that retreatment with barzolvolimab significantly improves urticaria control following symptom recurrence. The company will share details of multiple presentations during the event, highlighting the potential of barzolvolimab as a first-in-class treatment option. Celldex is also engaged in ongoing Phase 3 studies for CSU and ColdU/SD, as well as investigating other indications.
Potential Positives
- Celldex has multiple presentations accepted at a prominent medical conference (AAAAI Annual Meeting), highlighting its commitment to advancing research in allergic conditions.
- New data regarding barzolvolimab's efficacy in treating urticaria will be presented, showcasing the potential for rapid improvement in patient symptoms, which is significant for clinical stakeholders.
- Barzolvolimab is positioned as a first-in-class treatment with a novel mechanism of action, suggesting potential competitive advantage in the market for chronic urticaria therapies.
- The ongoing Phase 3 studies indicate continued investment in research and development, emphasizing the company’s focus on expanding treatment options for patients with serious conditions.
Potential Negatives
- The press release highlights the company's ongoing Phase 2 studies, which may indicate that barzolvolimab has not yet advanced to later stages, suggesting potential delays or challenges in bringing the treatment to market.
- The mention of risks and uncertainties related to clinical testing and regulatory approvals in the forward-looking statements could raise concerns among investors about the company's ability to successfully commercialize barzolvolimab.
- The company's limited experience in bringing programs through Phase 3 clinical trials may cast doubt on their capability to manage current and future trials effectively, potentially affecting investor confidence.
FAQ
What is barzolvolimab used for?
Barzolvolimab is designed to treat chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism.
When will the presentations take place?
The presentations will occur during the AAAAI Annual Meeting from February 27 to March 2, 2026.
Where can I find the presentation details?
All presentation details will be posted on the Celldex website on the respective dates and times.
What new data will be presented as a late breaker?
The late breaker will highlight how retreatment with barzolvolimab improves urticaria control after symptom recurrence.
What type of clinical study is barzolvolimab undergoing?
Barzolvolimab is currently being studied in Phase 3 trials for chronic spontaneous urticaria and cold urticaria.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLDX Insider Trading Activity
$CLDX insiders have traded $CLDX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CLDX stock by insiders over the last 6 months:
- RICHARD M. WRIGHT sold 49,298 shares for an estimated $1,183,176
- FREDDY A. JIMENEZ (SVP & GENERAL COUNSEL) sold 4,166 shares for an estimated $121,209
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLDX Hedge Fund Activity
We have seen 80 institutional investors add shares of $CLDX stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,279,605 shares (+39.3%) to their portfolio in Q4 2025, for an estimated $61,914,071
- POINT72 ASSET MANAGEMENT, L.P. removed 2,135,585 shares (-54.8%) from their portfolio in Q4 2025, for an estimated $58,002,488
- BRAIDWELL LP added 1,266,420 shares (+214.0%) to their portfolio in Q4 2025, for an estimated $34,395,967
- STATE STREET CORP added 555,579 shares (+19.5%) to their portfolio in Q4 2025, for an estimated $15,089,525
- ADAR1 CAPITAL MANAGEMENT, LLC added 537,325 shares (+491.0%) to their portfolio in Q4 2025, for an estimated $14,593,747
- COMMODORE CAPITAL LP removed 463,335 shares (-15.3%) from their portfolio in Q4 2025, for an estimated $12,584,178
- DIMENSIONAL FUND ADVISORS LP added 394,633 shares (+153.5%) to their portfolio in Q4 2025, for an estimated $10,718,232
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLDX Analyst Ratings
Wall Street analysts have issued reports on $CLDX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 10/21/2025
- Barclays issued a "Underweight" rating on 10/13/2025
To track analyst ratings and price targets for $CLDX, check out Quiver Quantitative's $CLDX forecast page.
$CLDX Price Targets
Multiple analysts have issued price targets for $CLDX recently. We have seen 3 analysts offer price targets for $CLDX in the last 6 months, with a median target of $48.0.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $24.0 on 12/17/2025
- Joseph Catanzaro from Mizuho set a target price of $48.0 on 10/21/2025
- Edward Nash from Canaccord Genuity set a target price of $62.0 on 09/17/2025
Full Release
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, February 27 – March 2.
New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented as a late breaker, highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence.
All presentations will be posted on the Celldex website at the dates/times listed below. Presentation details are as follows:
Trial: Phase 2 ColdU and SD Study
Presentation:
Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 072
Location: Convention Center, Level 2, Hall E
Trial: Phase 2 CSU Study
Presentation:
Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 075
Location: Convention Center, Level 2, Hall E
Trial: Phase 2 ColdU and SD Study
Presentation:
Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria
Session Date / Time: 3/1/2026, 9:45 am - 10:45 am
Title: Late Breaking Poster Session II
Type: Poster Session LB
Poster Number: L41
Location: Convention Center, Level 2, Hall E
About Barzolvolimab
Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease. Based on data from robust, randomized, placebo controlled Phase 2 studies, barzolvolimab has significant potential as a first in class and best in disease treatment option for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is currently being studied in Phase 3 studies in CSU and ColdU/SD and Phase 2 studies in prurigo nodularis (PN) and atopic dermatitis (AD), with additional indications planned for the future.
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit
www.celldex.com
.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
[email protected]
Patrick Till
Meru Advisors
(484) 788-8560
[email protected]
